China’s July CPI reading of 0.5% signals gently rising prices and a consumer backdrop that many investors have been waiting for. Stable inflation can keep liquidity conditions relatively supportive and draws more attention to Chinese consumer and retail stocks that are closely tied to everyday spending. This article walks through 3 stocks that appear positively exposed to this shift, helping you decide which stories deserve a closer look now.
The stocks covered below are just a starting sample, and the full screen surfaced 15 more large Chinese consumer and retail companies with equally interesting stories that are not covered here. To identify your own highest conviction ideas, head straight to the Consumer and Retail Stocks in China screener to filter and analyze the wider opportunity set.
Sichuan SwellfunLtd (SHSE:600779)
Sichuan SwellfunLtd is a Chengdu based liquor producer best known for its Shui Jing Fang baijiu brands, selling premium spirits across China and overseas. The business is highly focused, with essentially all of its CN¥2.9b revenue coming from the wine business. At a market value of around CN¥13.9b, Sichuan SwellfunLtd sits in the mid cap bracket of China’s consumer space.
Sichuan SwellfunLtd sits at the crossroads of several themes that may matter for investors. It is a pure play on Chinese spirits consumption at a time when inflation is mild and consumer spending appears more stable. However, the stock carries mixed signals on valuation, margins and governance. Forecast earnings growth and a strong brand portfolio are points of appeal for investors seeking quality exposure to Chinese consumption. At the same time, falling profit margins, relatively low current returns on equity and board structure concerns mean this is not a straightforward story. The tension between these strengths and risks is what makes Sichuan SwellfunLtd a candidate for closer inspection in the screener.
Sichuan SwellfunLtd’s premium baijiu story looks compelling, yet the real puzzle sits in how forecast earnings, margins and governance fit together. Pull up the 2 key rewards and 2 important warning signs to see what might be quietly shaping the next chapter.
Build your own premium consumer shortlist
Sichuan SwellfunLtd and the two other stocks in this article all came from a single set of screener filters, but the real value for you is in tailoring those filters yourself. Use our flexible Screener to mix metrics like valuation, future growth, balance sheet strength and risk checks, or start with one of our curated Investing Ideas.
Baolingbao BiologyLtd (SZSE:002286)
Baolingbao BiologyLtd is a Yucheng based manufacturer of functional sugars and related ingredients used in dairy, drinks, snacks, health supplements and animal nutrition, selling into both Chinese and international food producers. Almost all of its roughly CN¥2.8b revenue comes from agricultural and sideline food processing, which keeps the business tightly linked to everyday consumer products. With a market value of about CN¥3.0b, Baolingbao BiologyLtd sits in the smaller end of China’s listed food manufacturers.
Baolingbao BiologyLtd is closely tied to the current CPI story, as a significant supplier into food and beverage categories that tend to move with everyday consumer demand. The stock trades on a P/E below both the wider China market and local food peers. At the same time, profit margins and returns on equity are still modest, the dividend record has been uneven, funding leans on higher risk borrowings and the board and management team are relatively new. For investors who want direct exposure to China’s consumer activity through food ingredients, the balance of these characteristics may make Baolingbao BiologyLtd a candidate for further research in a screener.
Baolingbao BiologyLtd’s low P/E and tight link to everyday food demand suggest potential upside that many investors may be overlooking. Pull up the 4 key rewards and 1 important warning sign to explore what the valuation might be masking.
Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016)
Shandong Bailong Chuangyuan Bio-Tech produces dietary fibers, prebiotics and starch-based sweeteners that go into everyday products such as drinks, dairy, health supplements and animal feed for customers in China and overseas. The company is valued at about CN¥9.0b, which places it in the mid cap range among Chinese consumer ingredient suppliers.
Shandong Bailong Chuangyuan Bio-Tech is part of the consumer staples segment that July’s 0.5% CPI reading highlights. Mild inflation and steadier demand can support ingredient suppliers that serve beverage, dairy and health focused brands. The company reports strong recent earnings growth, a P/E below the wider food industry and net margins around 28%. At the same time, investors need to weigh board independence, reliance on higher risk funding and a dividend that is not well covered by free cash flow. For anyone tracking quality exposure to food and beverage demand linked to stable inflation, this mix of strengths and pressure points may warrant a closer look.
Shandong Bailong Chuangyuan Bio-Tech’s earnings strength and mid cap scale could be masking a far bigger story around quality and risk. Pull up the 4 key rewards and 2 important warning signs (1 is major!) to explore the one factor that could flip the script
Seeking Fresh Alternatives Beyond These Stocks
Some stocks move first while the rest of the market watches. Scan fresh ideas with real momentum before they are fully priced in and under the radar for now, and consider acting promptly.
- Spot companies with strong cash generation before they attract wider attention by running the curated 255 high quality undervalued stocks while the window for a cheaper entry may still be open.
- Track potential income workhorses that may keep paying investors while others are chasing headlines by scanning the hand picked 439 dividend fortresses before yields change.
- Review fast growing automation trends by using the focused 36 robotics and automation stocks while many of these stocks may still be flying under most investors’ radars.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com